Show simple item record

dc.contributor.author
Montopoli, Monica
dc.contributor.author
Zumerle, Sara
dc.contributor.author
Vettor, Roberto
dc.contributor.author
Rugge, Massimo
dc.contributor.author
Zorzi, Manuel
dc.contributor.author
Catapano, Carlo V.
dc.contributor.author
Carbone, G.M.
dc.contributor.author
Cavalli, Andrea
dc.contributor.author
Pagano, Francesco
dc.contributor.author
Ragazzi, Eugenio
dc.contributor.author
Prayer-Galetti, Tommaso
dc.contributor.author
Alimonti, Andrea
dc.date.accessioned
2020-08-07T09:21:43Z
dc.date.available
2020-05-21T02:45:02Z
dc.date.available
2020-05-22T11:50:40Z
dc.date.available
2020-06-29T11:54:50Z
dc.date.available
2020-08-07T09:21:43Z
dc.date.issued
2020-08
dc.identifier.issn
1569-8041
dc.identifier.issn
0923-7534
dc.identifier.other
10.1016/j.annonc.2020.04.479
en_US
dc.identifier.uri
http://hdl.handle.net/20.500.11850/416200
dc.description.abstract
Background Cell entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) depends on binding of the viral spike (S) proteins to angiotensin-converting enzyme 2 and on S protein priming by TMPRSS2. Inhibition of TMPRSS2 may work to block or decrease the severity of SARS-CoV-2 infections. Intriguingly, TMPRSS2 is an androgen-regulated gene that is up-regulated in prostate cancer where it supports tumor progression and is involved in a frequent genetic translocation with the ERG gene. First- or second-generation androgen-deprivation therapies (ADTs) decrease the levels of TMPRSS2. Here we put forward the hypothesis that ADTs may protect patients affected by prostate cancer from SARS-CoV-2 infections. Materials and methods We extracted data regarding 9280 patients (4532 males) with laboratory-confirmed SARS-CoV-2 infection from 68 hospitals in Veneto, one of the Italian regions that was most affected by the coronavirus disease 2019 (COVID-19) pandemic. The parameters used for each COVID-19-positive patient were sex, hospitalization, admission to intensive care unit, death, tumor diagnosis, prostate cancer diagnosis, and ADT. Results There were evaluable 9280 SARS-CoV-2-positive patients in Veneto on 1 April 2020. Overall, males developed more severe complications, were more frequently hospitalized, and had a worse clinical outcome than females. Considering only the Veneto male population (2.4 million men), 0.2% and 0.3% of non-cancer and cancer patients, respectively, tested positive for SARS-CoV-2. Comparing the total number of SARS-CoV-2-positive cases, prostate cancer patients receiving ADT had a significantly lower risk of SARS-CoV-2 infection compared with patients who did not receive ADT (OR 4.05; 95% CI 1.55–10.59). A greater difference was found comparing prostate cancer patients receiving ADT with patients with any other type of cancer (OR 4.86; 95% CI 1.88–12.56). Conclusion Our data suggest that cancer patients have an increased risk of SARS-CoV-2 infections compared with non-cancer patients. However, prostate cancer patients receiving ADT appear to be partially protected from SARS-CoV-2 infections.
en_US
dc.language.iso
en
en_US
dc.publisher
Elsevier
en_US
dc.subject
androgen-deprivation therapy
en_US
dc.subject
prostate cancer
en_US
dc.subject
COVID-19
en_US
dc.title
Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (n=4532)
en_US
dc.type
Journal Article
dc.date.published
2020-05-06
ethz.journal.title
Annals of Oncology
ethz.journal.volume
31
en_US
ethz.journal.issue
8
en_US
ethz.journal.abbreviated
Ann Oncol
ethz.pages.start
1040
en_US
ethz.pages.end
1045
en_US
ethz.identifier.wos
ethz.identifier.scopus
ethz.publication.place
Oxford
en_US
ethz.publication.status
published
en_US
ethz.leitzahl
ETH Zürich::00002 - ETH Zürich::00012 - Lehre und Forschung::00007 - Departemente::02070 - Dep. Gesundheitswiss. und Technologie / Dep. of Health Sciences and Technology::02540 - Institut für Translationale Medizin / Institute of Translational Medicine::09703 - Alimonti, Andrea / Alimonti, Andrea
en_US
ethz.leitzahl.certified
ETH Zürich::00002 - ETH Zürich::00012 - Lehre und Forschung::00007 - Departemente::02070 - Dep. Gesundheitswiss. und Technologie / Dep. of Health Sciences and Technology::02540 - Institut für Translationale Medizin / Institute of Translational Medicine::09703 - Alimonti, Andrea / Alimonti, Andrea
en_US
ethz.date.deposited
2020-05-21T02:45:07Z
ethz.source
SCOPUS
ethz.eth
yes
en_US
ethz.availability
Metadata only
en_US
ethz.rosetta.installDate
2020-08-07T09:21:57Z
ethz.rosetta.lastUpdated
2021-02-15T15:57:50Z
ethz.rosetta.versionExported
true
ethz.COinS
ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.atitle=Androgen-deprivation%20therapies%20for%20prostate%20cancer%20and%20risk%20of%20infection%20by%20SARS-CoV-2:%20a%20population-based%20study%20(n=4532)&rft.jtitle=Annals%20of%20Oncology&rft.date=2020-08&rft.volume=31&rft.issue=8&rft.spage=1040&rft.epage=1045&rft.issn=1569-8041&0923-7534&rft.au=Montopoli,%20Monica&Zumerle,%20Sara&Vettor,%20Roberto&Rugge,%20Massimo&Zorzi,%20Manuel&rft.genre=article&rft_id=info:doi/10.1016/j.annonc.2020.04.479&
 Search print copy at ETH Library

Files in this item

FilesSizeFormatOpen in viewer

There are no files associated with this item.

Publication type

Show simple item record